Form 4: Apimeds Director Granted Stock Options

Apimeds Pharmaceuticals US, Inc. director Carol A O'Donnell was granted 3,000 stock options with an exercise price of $1.92, vesting over three years.

Summary

• Director Carol A O'Donnell of Apimeds Pharmaceuticals US, Inc. was granted 3,000 stock options.
• The stock options have an exercise price of $1.92 per share.
• The options were granted on October 15, 2025, and expire on October 15, 2035.
• Vesting occurs in quarterly installments beginning October 1, 2025, with full vesting after three years, contingent on continued service.
• Exercisability is conditional upon stockholder approval of an amendment to the issuer's incentive plan to increase the number of shares available for issuance.
• The options will vest in full immediately upon the occurrence of a Change in Control, as defined in the plan.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive event as it aligns management incentives with shareholder value, though the immediate impact on the company's operational or financial performance is neutral. The condition for exercisability introduces a minor uncertainty.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director over a three-year period.

Risks

• The exercisability of the stock options is contingent on obtaining stockholder approval for an amendment to the incentive plan, which is not guaranteed.
• Future dilution for existing shareholders could occur if the options are exercised after vesting.

Future Outlook

The future exercisability of these options is dependent on stockholder approval of an amendment to the company's incentive plan. The options are designed to incentivize long-term service and performance, with full vesting accelerated upon a Change in Control.

Industry Context

Stock option grants are a common form of executive and director compensation in the pharmaceutical and biotechnology industries, used to attract and retain talent and align their interests with company performance and shareholder value. The exercise price of $1.92 reflects the stock's value at the time of grant.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of options; improved alignment of director's interests with shareholder value.
• Director (Carol A O'Donnell): Receives equity-based compensation, incentivizing long-term commitment and performance.

Next Steps

• Obtain stockholder approval for an amendment to the issuer's incentive plan to increase the number of shares available for issuance.

Key Dates

Keywords

Apimeds Pharmaceuticals, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, APUS